Synta Pharmaceuticals

Madrigal says NASH drug also works in cholesterol disorder

Madrigal Pharma is celebrating after its lead drug, MGL-3196, hit the mark in a phase 2 trial in the second of its two target indications: heterozygous familial hypercholesterolemia.

Phil Taylor Feb 8, 2018 10:36am

Involved in the propertys development are Stonehill Taylor for interior design and Blackney Hayes Architects and Powers

Madrigal’s NASH drug hits liver fat in midstage test

Dec 6, 2017 7:47am

After PhIII failure Synta announces merger, shifts R&D focus

Apr 14, 2016 9:53am

Synta Pharmaceuticals Reports Third-Quarter 2010 Financial Results and Clinical Update

Nov 4, 2010 8:23am